George Wilding
University of Wisconsin, Madison
7
7
6
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+14 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (7)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Brenda Sandmaier
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
Stanislaw R. Burzynski, MD, PhD
Burzynski Research Institute
Shared therapeutic areas:
Thomas E. Witzig, MD
Mayo Clinic
Shared therapeutic areas:
Worked with same sponsors:
Mary Horowitz, MD
Center for International Blood and Marrow Transplant Research
Shared therapeutic areas:
Worked with same sponsors:
Ingrid Mayer, MD
Vanderbilt-Ingram Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Heinz-Josef Lenz, MD
University of Southern California
Shared therapeutic areas:
Worked with same sponsors:
Scot C. Remick, MD
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Corey J. Langer, MD
Fox Chase Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Gustavo Leone
Medical University of South Carolina, Hollings Cancer Center
Shared therapeutic areas:
Jorge Cortes, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (7)
Showing 7 of 7 trials
Combination Chemotherapy in Treating Patients With Advanced Cancer That is Metastatic or Cannot Be Removed By Surgery
Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors
3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors
Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors
Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors
All 7 trials loaded